Methods and compositions for matrix preparation

Polymerizing collagen through a single mixing step and using a kit that simulates physiological conditions, the production consistency and functional characteristics of the preparation of collagen matrix are solved, achieving highly predictable and reproducible collagen self-assembly and biocompatibility, avoiding the Damage to collagen by ultraviolet radiation.

CN110446500BActive Publication Date: 2024-11-26GENIPHYS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880019401.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-01-31
Filing Date
2018-01-31
Publication Date
2024-11-26
Estimated Expiration
2039-02-13

AI Technical Summary

Technical Problem

The prior art is difficult to ensure the production consistency and functional properties of the preparation of collagen-based substrates, and conventional multi-step polymerization methods are not predictable and reproducible for collagen self-assembly, and ultraviolet radiation can impair collagen fibril formation.

Method used

Polymerize collagen using a single mixing step, using kits that simulate physiological conditions, including buffer solutions and collagen compositions, avoiding magnesium or manganese ions, and maintaining collagen's polymerization ability and biocompatible through incubation and UV radiation sterilization.

Benefits of technology

A highly predictable and reproducible collagen matrix self-assembly is achieved, maintaining polymerization characteristics and biocompatibility, avoiding damage to collagen by ultraviolet radiation, and improving production consistency and functional stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110446500B_ABST
    Figure CN110446500B_ABST
Patent Text Reader

Abstract

The present invention relates to methods of preparing matrices and compositions for use in these methods. In particular, the present invention relates to methods of preparing collagen matrices and compositions for use in these methods, including kits and implant compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority under 35 USC §119(e) to U.S. Provisional Application Serial No. 62 / 452,564, filed on January 31, 2017, the entire disclosure of which is incorporated herein by reference. Technical Field

[0003] The present invention relates to methods of preparing matrices and compositions for use in these methods. In particular, the present invention relates to methods of preparing collagen matrices and compositions for use in these methods, including kits and implant compositions.

[0004] Background and Summary of the Invention

[0005] Extracellular matrix plays a key role in the function of tissue and organ, such as differentiation, wound healing, adhesion and cell migration and proliferation during intercellular communication, embryogenesis. Extracellular matrix graft constructs obtained from natural sources or prepared in a synthetic manner can be used as solid and injectable tissue graft compositions of these two forms for in vivo tissue remodeling or for in vitro applications, for example, for research purposes. The main component of extracellular matrix is ​​collagen. Some dissolved collagen compositions (comprising purified collagen compositions) have matrix formation ability, and can also be used as solid and injectable tissue graft compositions of these two forms for in vivo tissue remodeling or for in vitro purposes. In fact, this matrix based on collagen has extensive research and medical applications, including wounds and hemostatic dressings, as surgical implants, as substrates for tissue engineering medical products, as delivery carriers for therapeutic cells or molecules, and as the three-dimensional in vitro tissue system for basic research (comprising drug development and toxicity testing).

[0006] In order to ensure high production consistency of collagen-based matrices for medical and research applications and low batch-to-batch variation in the functional properties of collagen used to prepare collagen-based matrices, standardized processes and reagents are required for inducing collagen self-assembly and for customizing collagen-based matrices.

[0007] Therefore, the inventors have developed a robust method that uses a single mixing step for collagen polymerization, using reagents that simulate physiological conditions to support the supramolecular self-assembly of collagen as observed in vivo. In addition, the methods and reagents used in the methods described herein are based on physiological reactions, such as the viscoelasticity (e.g., shear storage modulus measured in oscillating shear and matrix stiffness) of the self-assembled matrix that varies with the collagen concentration in the polymerization reaction. The methods and compositions described herein produce collagen-based matrices that have properties similar to conventional multi-step polymerization methods involving multiple mixing steps for collagen polymerization, which conventional multi-step polymerization methods include mixing the collagen composition with a buffer solution, then mixing with, for example, an alkali (such as NaOH) to induce polymerization, and then optionally mixing with other reagents. The methods and compositions developed by the inventors have produced highly predictable and reproducible in vitro cell and in vivo host responses to the self-assembled collagen matrix. On the other hand, the inventors have developed a method for sterilizing collagen, collagen composition, collagen matrix, collagen solution, and freeze-dried collagen described herein while maintaining polymerization capacity (e.g., shear storage modulus) by using ultraviolet radiation. The retention of the ability to polymerize is contrary to previous studies reporting that ultraviolet radiation negatively affects collagen fibril formation (Mentor et al., Photodermatology, Photoimmunology & Photomedicine, 2001; Miyata et al., Biochem. Biophys. Acta, 1971; Sudoh and Noda, Connect. Tissue Res., 1972). In one embodiment, a method for preparing a matrix is ​​provided. The method includes polymerizing collagen using a single mixing step, including mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix.

[0008] In another embodiment, a method for preparing a matrix is ​​provided, comprising polymerizing collagen by mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix, wherein the buffer solution does not contain magnesium ions or manganese ions.

[0009] In yet another embodiment, a method of preparing a matrix is ​​provided. The method includes polymerizing collagen using a single mixing step, the single mixing step including mixing a collagen composition with a buffer solution to form a collagen solution, wherein the collagen in the collagen solution is polymerized to form the matrix.

[0010] In yet other embodiments, a collagen matrix prepared according to any of the foregoing methods is provided. In yet another embodiment, a kit comprising a collagen composition and a buffer solution is provided. In another embodiment, a kit comprising lyophilized collagen, a hydrochloric acid solution, and a buffer solution is provided.

[0011] Several further embodiments are described by the following enumerated clauses. Any applicable combination of these embodiments is also contemplated.

[0012] 1. A method for preparing a matrix, the method comprising polymerizing collagen using a single mixing step, comprising mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix.

[0013] 2. The method of clause 1, comprising incubating the collagen solution at greater than about 25°C to promote polymerization of collagen in the collagen solution.

[0014] 3. The method of clause 1 or 2, comprising incubating the collagen solution at about 37°C to promote polymerization of collagen in the collagen solution.

[0015] 4. The method of any one of clauses 1 to 3, wherein the collagen comprises collagen oligomers.

[0016] 5. The method of any one of clauses 1 to 4, wherein the collagen consists of collagen oligomers.

[0017] 6. The method of clause 4, wherein the collagen further comprises telocollagen.

[0018] 7. The method according to clause 4, wherein the collagen further comprises atelocollagen.

[0019] 8. The method according to clause 4, wherein the collagen comprising collagen oligomers is obtained from tissues containing collagen oligomers, obtained from cells producing collagen oligomers, or obtained by chemically cross-linking collagen to obtain the collagen oligomers.

[0020] 9. The method of any one of clauses 1 to 8, wherein the collagen is derived from porcine skin tissue.

[0021] 10. The method of any one of clauses 1 to 9, wherein the collagen composition further comprises an acid.

[0022] 11. The method of clause 10, wherein the acid is selected from the group consisting of hydrochloric acid, acetic acid, lactic acid, formic acid, citric acid, sulfuric acid and phosphoric acid.

[0023] 12. The method of clause 11, wherein the acid is hydrochloric acid.

[0024] 13. The method of clause 12, wherein the hydrochloric acid is about 0.005N to about 0.1N hydrochloric acid.

[0025] 14. The method of clause 12 or 13, wherein the hydrochloric acid is about 0.01N hydrochloric acid.

[0026] 15. The method of any one of clauses 1 to 14, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 40 mg / ml.

[0027] 16. The method of any one of clauses 1 to 15, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 5 mg / ml.

[0028] 17. The method of any one of clauses 1 to 16, wherein the concentration of the collagen in the collagen solution is about 0.5 mg / ml to about 4 mg / ml.

[0029] 18. The method of any one of clauses 1 to 13, wherein the collagen composition is sterilized.

[0030] 19. The method of any one of clauses 1 to 18, wherein the collagen composition, the collagen solution or the collagen matrix is ​​sterilized by a method selected from the group consisting of exposure to chloroform, virus filtration, sterile filtration, ultraviolet radiation, gamma irradiation, electron beam, and combinations thereof.

[0031] 20. The method of any one of clauses 1 to 19, wherein the collagen composition is sterilized by filtration.

[0032] 21. The method of any one of clauses 1 to 20, wherein the buffer solution comprises about 0.03 mM to about 0.2 mM MgCl2.

[0033] 22. The method of any one of clauses 1 to 20, wherein the buffer solution comprises about 0.002 mM to about 0.02 mM MgCl2.

[0034] 23. The method of any one of clauses 1 to 20, wherein the buffer solution comprises less than about 0.02 mM MgCl2.

[0035] 24. The method of any one of clauses 1 to 20, wherein the buffer solution does not contain MgCl2.

[0036] 25. The method of any one of clauses 1 to 24, wherein the buffer solution further comprises about 0.3 mM to about 3 mM KH2PO4.

[0037] 26. The method of any one of clauses 1 to 25, wherein the buffer solution further comprises about 1 mM to about 10 M Na2HPO4.

[0038] 27. The method of any one of clauses 1 to 26, wherein the buffer solution further comprises about 0.1 mM to about 4 mM KCl.

[0039] 28. The method of any one of clauses 1 to 27, wherein the buffer solution further comprises about 0.02 M to about 0.3 M NaCl.

[0040] 29. The method of any one of clauses 1 to 28, wherein the buffer solution further comprises about 0.002N to about 0.02N NaOH.

[0041] 30. The method of any one of clauses 1 to 29, wherein the buffer solution further comprises about 0.5 wt % to about 5 wt % glucose.

[0042] 31. The method of any one of clauses 1 to 29, wherein the buffer solution comprises about 0.5 wt% or less glucose.

[0043] 32. The method of any one of clauses 1 to 31, further comprising adding cells to the collagen solution.

[0044] 33. The method of any one of clauses 1 to 32, wherein the matrix comprises collagen fibrils.

[0045] 34. A collagen matrix prepared according to the method of any one of clauses 1 to 33.

[0046] 35. The collagen matrix of clause 34, wherein the collagen matrix is ​​a medical implant.

[0047] 36. The collagen matrix of clause 35, wherein the medical graft has a use selected from the group consisting of: a tissue graft material, an injectable graft material, a wound dressing, a hemostatic dressing, a delivery vehicle for therapeutic cells, and a delivery vehicle for therapeutic agents.

[0048] 37. The collagen matrix of clause 35, wherein the collagen matrix is ​​used for research purposes.

[0049] 38. The collagen matrix of clause 37, wherein the collagen matrix is ​​used for drug toxicity testing or drug development.

[0050] 39. A kit comprising a collagen composition and a buffer solution.

[0051] 40. The kit of clause 39, wherein the buffer solution comprises about 0.03 mM to about 0.2 mM MgCl2.

[0052] 41. The kit of clause 39, wherein the buffer solution comprises about 0.002 mM to about 0.02 mM MgCl2.

[0053] 42. The kit of clause 39, wherein the buffer solution comprises less than about 0.02 mM MgCl2.

[0054] 43. The kit of clause 39, wherein the buffer solution does not contain MgCl2.

[0055] 44. The kit of any one of clauses 39 to 43, wherein the buffer solution further comprises about 0.003 M to about 0.03 M KH2PO4.

[0056] 45. The kit of any one of clauses 39 to 44, wherein the buffer solution further comprises about 0.01 M to about 0.1 M Na2HPO4.

[0057] 46. ​​The kit of any one of clauses 39 to 45, wherein the buffer solution further comprises about 0.001 M to about 0.04 M KCl.

[0058] 47. The kit of any one of clauses 39 to 46, wherein the buffer solution further comprises about 0.2 M to about 3.0 M NaCl.

[0059] 48. The kit of any one of clauses 39 to 47, wherein the buffer solution further comprises about 0.02N to about 0.2N NaOH.

[0060] 49. The kit of any one of clauses 39 to 48, wherein the buffer solution further comprises about 0.2 wt % to about 5 wt % glucose.

[0061] 50. The kit of any one of clauses 39 to 48, wherein the buffer solution comprises about 0.5 wt% or less glucose.

[0062] 51. The kit of any one of clauses 39 to 50, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 40 mg / ml.

[0063] 52. The kit of any one of clauses 39 to 51, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 5 mg / ml.

[0064] 53. The kit of any one of clauses 39 to 52, wherein the collagen solution comprises about 0.005N hydrochloric acid to about 0.1N hydrochloric acid.

[0065] 54. The kit of any one of clauses 39 to 53, wherein the buffer solution is capable of polymerizing the collagen using a single mixing step comprising mixing the collagen composition with the buffer solution.

[0066] 55. The kit of any one of clauses 39 to 54, wherein the collagen composition and the buffer solution are in separate containers.

[0067] 56. The kit of clause 55, wherein the container is a sterilized vial.

[0068] 57. The kit of clause 55, wherein the container comprises separate compartments of a dual syringe.

[0069] 58. The kit of clause 57, wherein the double-barrel syringe comprises a mixing element.

[0070] 59. The kit of clause 57, wherein the double-barrel syringe is sterilized.

[0071] 60. The kit of any one of clauses 39 to 59, further comprising instructions for use of the components of the kit.

[0072] 61. A method for preparing a matrix, the method comprising polymerizing collagen by: mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix, wherein the buffer solution does not contain magnesium ions or manganese ions.

[0073] 62. The method of clause 61, comprising incubating the collagen solution at greater than about 25°C to promote polymerization of collagen in the collagen solution.

[0074] 63. The method of clause 61 or 62, comprising incubating the collagen solution at about 37°C to promote polymerization of collagen in the collagen solution.

[0075] 64. The method of any one of clauses 61 to 63, wherein the collagen comprises collagen oligomers.

[0076] 65. The method of any one of clauses 61 to 63, wherein the collagen consists of collagen oligomers.

[0077] 66. The method of clause 64, wherein the collagen further comprises telomere collagen.

[0078] 67. The method of clause 64, wherein the collagen further comprises atelocollagen.

[0079] 68. The method of clause 64, wherein the collagen comprising collagen oligomers is obtained from a tissue containing collagen oligomers, obtained from cells producing collagen oligomers, or obtained by chemically cross-linking the collagen to obtain the collagen oligomers.

[0080] 69. The method of any one of clauses 61 to 68, wherein the collagen is derived from porcine skin tissue.

[0081] 70. The method of any one of clauses 61 to 69, wherein the collagen composition further comprises an acid.

[0082] 71. The method of clause 70, wherein the acid is selected from the group consisting of hydrochloric acid, acetic acid, lactic acid, formic acid, citric acid, sulfuric acid and phosphoric acid.

[0083] 72. The method of clause 71, wherein the acid is hydrochloric acid.

[0084] 73. The method of clause 72, wherein the hydrochloric acid is about 0.005N to about 0.1N hydrochloric acid.

[0085] 74. The method of clause 72 or 73, wherein the hydrochloric acid is about 0.01 N hydrochloric acid.

[0086] 75. The method of any one of clauses 61 to 74, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 40 mg / ml.

[0087] 76. The method of any one of clauses 61 to 75, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 5 mg / ml.

[0088] 77. The method of any one of clauses 61 to 76, wherein the concentration of the collagen in the collagen solution is about 0.5 mg / ml to about 4 mg / ml.

[0089] 78. The method of any one of clauses 61 to 77, wherein the collagen composition is sterilized.

[0090] 79. The method of any one of clauses 61 to 78, wherein the collagen composition, the collagen solution or the collagen matrix is ​​sterilized by a method selected from the group consisting of exposure to chloroform, virus filtration, sterile filtration, ultraviolet radiation, gamma irradiation, electron beam, and combinations thereof.

[0091] 80. The method of any one of clauses 61 to 79, wherein the collagen composition is sterilized by filtration.

[0092] 81. The method of any one of clauses 61 to 80, wherein the buffer solution further comprises about 0.3 mM to about 3 mM KH2PO4.

[0093] 82. The method of any one of clauses 61 to 81, wherein the buffer solution further comprises about 1 mM to about 10 M Na2HPO4.

[0094] 83. The method of any one of clauses 61 to 82, wherein the buffer solution further comprises about 0.1 mM to about 4 mM KCl.

[0095] 84. The method of any one of clauses 61 to 83, wherein the buffer solution further comprises about 0.02 M to about 0.3 M NaCl.

[0096] 85. The method of any one of clauses 61 to 84, wherein the buffer solution further comprises about 0.002N to about 0.02N NaOH.

[0097] 86. The method of any one of clauses 61 to 85, wherein the buffer solution further comprises about 0.5 wt % to about 5 wt % glucose.

[0098] 87. The method of any one of clauses 61 to 85, wherein the buffer solution comprises about 0.5 wt % or less glucose.

[0099] 88. The method of any one of clauses 61 to 87, further comprising adding cells to the collagen solution.

[0100] 89. The method of any one of clauses 61 to 88, wherein the matrix comprises collagen fibrils.

[0101] 90. A collagen matrix prepared according to the method of any one of clauses 61 to 89.

[0102] 91. The collagen matrix of clause 90, wherein the collagen matrix is ​​a medical implant.

[0103] 92. The collagen matrix of clause 91, wherein the medical graft has a use selected from the group consisting of: a tissue graft material, an injectable graft material, a wound dressing, a hemostatic dressing, a delivery vehicle for therapeutic cells, and a delivery vehicle for therapeutic agents.

[0104] 93. The collagen matrix of clause 90, wherein the collagen matrix is ​​used for research purposes.

[0105] 94. The collagen matrix of clause 93, wherein the collagen matrix is ​​used for drug toxicity testing or drug development.

[0106] 95. A kit comprising freeze-dried collagen, a hydrochloric acid solution and a buffer solution.

[0107] 96. The kit of clause 95, wherein the buffer solution comprises about 0.03 mM to about 0.2 mM MgCl2.

[0108] 97. The kit of clause 95, wherein the buffer solution comprises about 0.002 mM to about 0.02 mM MgCl2.

[0109] 98. The kit of clause 95, wherein the buffer solution comprises less than about 0.02 mM MgCl2.

[0110] 99. The kit of clause 95, wherein the buffer solution does not contain MgCl2.

[0111] 100. The kit of any one of clauses 95 to 99, wherein the buffer solution further comprises about 0.003 M to about 0.03 M KH2PO4.

[0112] 101. The kit of any one of clauses 95 to 100, wherein the buffer solution further comprises about 0.01 M to about 0.1 M Na2HPO4.

[0113] 102. The kit of any one of clauses 95 to 101, wherein the buffer solution further comprises about 0.001 M to about 0.04 M KCl.

[0114] 103. The kit of any one of clauses 95 to 102, wherein the buffer solution further comprises about 0.2 M to about 3.0 M NaCl.

[0115] 104. The kit of any one of clauses 95 to 103, wherein the buffer solution further comprises about 0.02N to about 0.2N NaOH.

[0116] 105. The kit of any one of clauses 95 to 104, wherein the buffer solution further comprises about 0.2 wt % to about 5 wt % glucose.

[0117] 106. The kit of any one of clauses 95 to 105, wherein the buffer solution comprises about 0.5 wt % or less glucose.

[0118] 107. The kit of any one of clauses 95 to 106, wherein the hydrochloric acid solution comprises about 0.005N hydrochloric acid to about 0.1N hydrochloric acid.

[0119] 108. The kit of any one of clauses 95 to 107, wherein the buffer solution is capable of polymerizing collagen using a single mixing step comprising mixing the buffer solution with the lyophilized collagen reconstituted in the hydrochloric acid solution.

[0120] 109. The kit of any one of clauses 95 to 108, wherein the lyophilized collagen, the hydrochloric acid solution and the buffer solution are in separate containers.

[0121] 110. The kit of any one of clauses 95 to 109, further comprising instructions for use of the components of the kit.

[0122] 111. A method of preparing a matrix, the method comprising polymerizing collagen using a single mixing step, the single mixing step comprising mixing a collagen composition with a buffer solution to form a collagen solution, wherein the collagen in the collagen solution is polymerized to form the matrix.

[0123] 112. The method of any one of clauses 1 to 33, 61 to 89 or 111, wherein the collagen is soluble collagen.

[0124] 113. The method of any one of clauses 1 to 19, 21 to 33, 61 to 79, 81 to 89 or 111 to 112, wherein the collagen composition, the collagen solution and / or the collagen matrix is ​​sterilized using ultraviolet radiation.

[0125] 114. The method of clause 113, wherein the collagen matrix resulting from the polymerization of collagen retains polymeric properties relative to a non-irradiated collagen composition, a non-irradiated collagen solution, or a non-irradiated collagen matrix, respectively.

[0126] 115. The method of clause 114, wherein the polymer property is shear storage modulus.

[0127] 116. The method of any of clauses 113 to 115, wherein the radiation dose ranges from about 5 mJ / cm2 to about 800 mJ / cm2.

[0128] 117. The method of any of clauses 113 to 115, wherein the radiation dose ranges from about 30 mJ / cm2 to about 300 mJ / cm2.

[0129] 118. The method of any one of clauses 113 to 117, wherein the sterilization inactivates viruses.

[0130] 119. The collagen matrix of any one of clauses 34 to 38 or 90 to 94, wherein the collagen matrix is ​​sterilized using ultraviolet radiation.

[0131] 120. The collagen matrix of clause 119, wherein the collagen matrix retains polymeric properties relative to a non-irradiated collagen matrix.

[0132] 121. The collagen matrix of clause 120, wherein the polymeric property is shear storage modulus.

[0133] 122. The collagen matrix of any one of clauses 119 to 121, wherein the radiation dose ranges from about 5 mJ / cm2 to about 800 mJ / cm2.

[0134] 123. The collagen matrix of any one of clauses 119 to 121, wherein the radiation dose ranges from about 30 mJ / cm2 to about 300 mJ / cm2.

[0135] 124. The collagen matrix of any one of clauses 119 to 123, wherein the sterilization inactivates viruses.

[0136] 125. The kit of any one of clauses 39 to 60 or 95 to 110, wherein the collagen composition or freeze-dried collagen is sterilized using ultraviolet radiation.

[0137] 126. The kit of clause 125, wherein the collagen matrix resulting from the polymerization of collagen retains polymeric properties relative to a non-irradiated collagen composition or non-irradiated freeze-dried collagen, respectively.

[0138] 127. The kit of clause 126, wherein the polymeric property is shear storage modulus.

[0139] 128. A kit as described in any of clauses 125 to 127, wherein the radiation dose ranges from about 5 mJ / cm2 to about 800 mJ / cm2.

[0140] 129. The kit of any one of clauses 125 to 127, wherein the radiation dose ranges from about 30 mJ / cm2 to about 300 mJ / cm2.

[0141] 130. The kit of any one of clauses 125 to 129, wherein the sterilization inactivates viruses.

[0142] 131. The method of any one of clauses 1 to 19, 21 to 33, 61 to 79, 81 to 89 or 111 to 118, wherein the collagen composition, the collagen solution and / or the collagen matrix is ​​sterilized using UVC irradiation.

[0143] 132. The method of any one of clauses 1 to 19, 21 to 33, 61 to 79, 81 to 89 or 111 to 118, wherein the collagen composition, the collagen solution and / or the collagen matrix is ​​sterilized using UVC irradiation and sterile filtration.

[0144] 133. The collagen matrix of any one of clauses 34 to 38, 90 to 94 or 119 to 124, wherein the collagen matrix is ​​sterilized using UVC irradiation.

[0145] 134. The collagen matrix of any one of clauses 34 to 38, 90 to 94 or 119 to 124, wherein the collagen matrix is ​​sterilized using UVC irradiation and sterile filtration.

[0146] 135. The kit of any one of clauses 39 to 60, 95 to 110 or 125 to 130, wherein the collagen composition or the lyophilized collagen is sterilized using UVC irradiation.

[0147] 136. The kit of any one of clauses 39 to 60, 95 to 110 or 125 to 130, wherein the collagen composition or the lyophilized collagen is sterilized using UVC irradiation and sterile filtration. BRIEF DESCRIPTION OF THE DRAWINGS

[0148] Figure 1 Shown are the shear storage moduli of collagen-based matrices polymerized at different oligomer concentrations.The polymerization capacity of the single-step assembly is similar to that obtained with the conventional multi-step process.

[0149] Figure 2 It was shown that self-assembled matrices prepared using multi-step and single-step processes showed similar biocompatibility and cellular responses. Figure 2 a) or single step ( Figure 2 b) process, human adipose-derived stem cells were used to form three-dimensional collagen-fibril tissue constructs. After 4 days, the constructs were fixed, stained with phalloidin, and visualized using confocal microscopy.

[0150] Figure 3 A multi-step process is shown.

[0151] Figure 4 A single step process is shown.

[0152] Figure 5 Shown is a single-step process that enables user-tailored formulation of self-assembled collagen matrices based on starting collagen oligomer concentrations.

[0153] Figure 6It is shown that research-grade and medical-grade formulations of oligomers show similar non-inflammatory tissue regeneration responses after subcutaneous injection in mice. Research-grade oligomers, medical-grade oligomers and IntegraFlowable were injected subcutaneously (200 μl) in mice. After 4 weeks, the implantation sites were harvested, fixed and prepared for histopathological analysis. The images show cross-sections of untreated skin (control; A), Integra Flowable (B), research-grade oligomers (C) and medical-grade oligomers (D).

[0154] Figure 7 The shear storage modulus of the collagen matrix polymerized from collagen treated with 0 (untreated control), 30 mJ / cm 2 (1 minute irradiation) and 300mJ / cm 2 (10 minutes of irradiation) dose of UVC radiation treatment. DETAILED DESCRIPTION

[0155] As used herein, "sterilization" refers to the removal of contaminants, including but not limited to infectious agents. For example, contaminants (e.g., viruses) can be removed by inactivating the contaminant (whether infectious or not), reducing the number or amount of the contaminant, or by inhibiting the activity of the contaminant.

[0156] As used herein, "purification" refers to the removal of contaminants, including but not limited to cellular contaminants, nucleotide contaminants, and endotoxins.

[0157] It means inactivating all viruses (whether infectious or not), reducing the number of infectious viruses, or inhibiting the activity of viruses (whether infectious or not).

[0158] As used herein, "an oligomer" or "oligomers" with respect to collagen refers to collagen monomers (also called terminal collagen) covalently linked to each other (eg, collagen monomers linked to each other to form dimers, trimers, etc.).

[0159] In one embodiment, a method for preparing a matrix is ​​provided. The method includes polymerizing collagen using a single mixing step, including mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix.

[0160] In another embodiment, a method for preparing a matrix is ​​provided, comprising polymerizing collagen by mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix, wherein the buffer solution does not contain magnesium ions or manganese ions.

[0161] In yet another embodiment, a method of preparing a matrix is ​​provided. The method includes polymerizing collagen using a single mixing step, the single mixing step including mixing a collagen composition with a buffer solution to form a collagen solution, wherein the collagen in the collagen solution is polymerized to form the matrix.

[0162] In yet other embodiments, a collagen matrix prepared according to any of the foregoing methods is provided. In yet another embodiment, a kit comprising a collagen composition and a buffer solution is provided. In another embodiment, a kit comprising lyophilized collagen, a hydrochloric acid solution, and a buffer solution is provided.

[0163] Several additional embodiments are described by the following enumerated clauses. Any applicable combination of these embodiments is also contemplated, and any applicable combination of these embodiments with embodiments described in this "Detailed Description" of the present application is also contemplated.

[0164] 1. A method for preparing a matrix, the method comprising polymerizing collagen using a single mixing step, comprising mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix.

[0165] 2. The method of clause 1, comprising incubating the collagen solution at greater than about 25°C to promote polymerization of collagen in the collagen solution.

[0166] 3. The method of clause 1 or 2, comprising incubating the collagen solution at about 37°C to promote polymerization of collagen in the collagen solution.

[0167] 4. The method of any one of clauses 1 to 3, wherein the collagen comprises collagen oligomers.

[0168] 5. The method of any one of clauses 1 to 4, wherein the collagen consists of collagen oligomers.

[0169] 6. The method of clause 4, wherein the collagen further comprises telomere collagen.

[0170] 7. The method of clause 4, wherein the collagen further comprises atelocollagen.

[0171] 8. The method according to clause 4, wherein the collagen comprising collagen oligomers is obtained from tissues containing collagen oligomers, obtained from cells producing collagen oligomers, or obtained by chemically cross-linking collagen to obtain the collagen oligomers.

[0172] 9. The method of any one of clauses 1 to 8, wherein the collagen is derived from porcine skin tissue.

[0173] 10. The method of any one of clauses 1 to 9, wherein the collagen composition further comprises an acid.

[0174] 11. The method of clause 10, wherein the acid is selected from the group consisting of hydrochloric acid, acetic acid, lactic acid, formic acid, citric acid, sulfuric acid and phosphoric acid.

[0175] 12. The method of clause 11, wherein the acid is hydrochloric acid.

[0176] 13. The method of clause 12, wherein the hydrochloric acid is about 0.005N to about 0.1N hydrochloric acid.

[0177] 14. The method of clause 12 or 13, wherein the hydrochloric acid is about 0.01N hydrochloric acid.

[0178] 15. The method of any one of clauses 1 to 14, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 40 mg / ml.

[0179] 16. The method of any one of clauses 1 to 15, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 5 mg / ml.

[0180] 17. The method of any one of clauses 1 to 16, wherein the concentration of the collagen in the collagen solution is about 0.5 mg / ml to about 4 mg / ml.

[0181] 18. The method of any one of clauses 1 to 13, wherein the collagen composition is sterilized.

[0182] 19. The method of any one of clauses 1 to 18, wherein the collagen composition, the collagen solution or the collagen matrix is ​​sterilized by a method selected from the group consisting of exposure to chloroform, virus filtration, sterile filtration, gamma irradiation, ultraviolet radiation, electron beam, and combinations thereof.

[0183] 20. The method of any one of clauses 1 to 19, wherein the collagen composition is sterilized by filtration.

[0184] 21. The method of any one of clauses 1 to 20, wherein the buffer solution comprises about 0.03 mM to about 0.2 mM MgCl2.

[0185] 22. The method of any one of clauses 1 to 20, wherein the buffer solution comprises about 0.002 mM to about 0.02 mM MgCl2.

[0186] 23. The method of any one of clauses 1 to 20, wherein the buffer solution comprises less than about 0.02 mM MgCl2.

[0187] 24. The method of any one of clauses 1 to 20, wherein the buffer solution does not contain MgCl2.

[0188] 25. The method of any one of clauses 1 to 24, wherein the buffer solution further comprises about 0.3 mM to about 3 mM KH2PO4.

[0189] 26. The method of any one of clauses 1 to 25, wherein the buffer solution further comprises about 1 mM to about 10 M Na2HPO4.

[0190] 27. The method of any one of clauses 1 to 26, wherein the buffer solution further comprises about 0.1 mM to about 4 mM KCl.

[0191] 28. The method of any one of clauses 1 to 27, wherein the buffer solution further comprises about 0.02 M to about 0.3 M NaCl.

[0192] 29. The method of any one of clauses 1 to 28, wherein the buffer solution further comprises about 0.002N to about 0.02N NaOH.

[0193] 30. The method of any one of clauses 1 to 29, wherein the buffer solution further comprises about 0.5 wt % to about 5 wt % glucose.

[0194] 31. The method of any one of clauses 1 to 29, wherein the buffer solution comprises about 0.5 wt% or less glucose.

[0195] 32. The method of any one of clauses 1 to 31, further comprising adding cells to the collagen solution.

[0196] 33. The method of any one of clauses 1 to 32, wherein the matrix comprises collagen fibrils.

[0197] 34. A collagen matrix prepared according to the method of any one of clauses 1 to 33.

[0198] 35. The collagen matrix of clause 34, wherein the collagen matrix is ​​a medical implant.

[0199] 36. The collagen matrix of clause 35, wherein the medical graft has a use selected from the group consisting of: a tissue graft material, an injectable graft material, a wound dressing, a hemostatic dressing, a delivery vehicle for therapeutic cells, and a delivery vehicle for therapeutic agents.

[0200] 37. The collagen matrix of clause 35, wherein the collagen matrix is ​​used for research purposes.

[0201] 38. The collagen matrix of clause 37, wherein the collagen matrix is ​​used for drug toxicity testing or drug development.

[0202] 39. A kit comprising a collagen composition and a buffer solution.

[0203] 40. The kit of clause 39, wherein the buffer solution comprises about 0.03 mM to about 0.2 mM MgCl2.

[0204] 41. The kit of clause 39, wherein the buffer solution comprises about 0.002 mM to about 0.02 mM MgCl2.

[0205] 42. The kit of clause 39, wherein the buffer solution comprises less than about 0.02 mM MgCl2.

[0206] 43. The kit of clause 39, wherein the buffer solution does not contain MgCl2.

[0207] 44. The kit of any one of clauses 39 to 43, wherein the buffer solution further comprises about 0.003 M to about 0.03 M KH2PO4.

[0208] 45. The kit of any one of clauses 39 to 44, wherein the buffer solution further comprises about 0.01 M to about 0.1 M Na2HPO4.

[0209] 46. ​​The kit of any one of clauses 39 to 45, wherein the buffer solution further comprises about 0.001 M to about 0.04 M KCl.

[0210] 47. The kit of any one of clauses 39 to 46, wherein the buffer solution further comprises about 0.2 M to about 3.0 M NaCl.

[0211] 48. The kit of any one of clauses 39 to 47, wherein the buffer solution further comprises about 0.02N to about 0.2N NaOH.

[0212] 49. The kit of any one of clauses 39 to 48, wherein the buffer solution further comprises about 0.2 wt % to about 5 wt % glucose.

[0213] 50. The kit of any one of clauses 39 to 48, wherein the buffer solution comprises about 0.5 wt% or less glucose.

[0214] 51. The kit of any one of clauses 39 to 50, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 40 mg / ml.

[0215] 52. The kit of any one of clauses 39 to 51, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 5 mg / ml.

[0216] 53. The kit of any one of clauses 39 to 52, wherein the collagen solution comprises about 0.005N hydrochloric acid to about 0.1N hydrochloric acid.

[0217] 54. The kit of any one of clauses 39 to 53, wherein the buffer solution is capable of polymerizing the collagen using a single mixing step comprising mixing the collagen composition with the buffer solution.

[0218] 55. The kit of any one of clauses 39 to 54, wherein the collagen composition and the buffer solution are in separate containers.

[0219] 56. The kit of clause 55, wherein the container is a sterilized vial.

[0220] 57. The kit of clause 55, wherein the container comprises separate compartments of a double barrel syringe.

[0221] 58. The kit of clause 57, wherein the double-barrel syringe comprises a mixing element.

[0222] 59. The kit of clause 57, wherein the double-barrel syringe is sterilized.

[0223] 60. The kit of any one of clauses 39 to 59, further comprising instructions for use of the components of the kit.

[0224] 61. A method for preparing a matrix, the method comprising polymerizing collagen by: mixing a collagen composition with a buffer solution to form a collagen solution, and polymerizing the collagen in the collagen solution to form the matrix, wherein the buffer solution does not contain magnesium ions or manganese ions.

[0225] 62. The method of clause 61, comprising incubating the collagen solution at greater than about 25°C to promote polymerization of collagen in the collagen solution.

[0226] 63. The method of clause 61 or 62, comprising incubating the collagen solution at about 37°C to promote polymerization of collagen in the collagen solution.

[0227] 64. The method of any one of clauses 61 to 63, wherein the collagen comprises collagen oligomers.

[0228] 65. The method of any one of clauses 61 to 63, wherein the collagen consists of collagen oligomers.

[0229] 66. The method of clause 64, wherein the collagen further comprises telomere collagen.

[0230] 67. The method of clause 64, wherein the collagen further comprises atelocollagen.

[0231] 68. The method of clause 64, wherein the collagen comprising collagen oligomers is obtained from a tissue containing collagen oligomers, obtained from cells producing collagen oligomers, or obtained by chemically cross-linking the collagen to obtain the collagen oligomers.

[0232] 69. The method of any one of clauses 61 to 68, wherein the collagen is derived from porcine skin tissue.

[0233] 70. The method of any one of clauses 61 to 69, wherein the collagen composition further comprises an acid.

[0234] 71. The method of clause 70, wherein the acid is selected from the group consisting of hydrochloric acid, acetic acid, lactic acid, formic acid, citric acid, sulfuric acid and phosphoric acid.

[0235] 72. The method of clause 71, wherein the acid is hydrochloric acid.

[0236] 73. The method of clause 72, wherein the hydrochloric acid is about 0.005N to about 0.1N hydrochloric acid.

[0237] 74. The method of clause 72 or 73, wherein the hydrochloric acid is about 0.01 N hydrochloric acid.

[0238] 75. The method of any one of clauses 61 to 74, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 40 mg / ml.

[0239] 76. The method of any one of clauses 61 to 75, wherein the concentration of the collagen in the collagen solution is about 0.1 mg / ml to about 5 mg / ml.

[0240] 77. The method of any one of clauses 61 to 76, wherein the concentration of the collagen in the collagen solution is about 0.5 mg / ml to about 4 mg / ml.

[0241] 78. The method of any one of clauses 61 to 77, wherein the collagen composition is sterilized.

[0242] 79. The method of any one of clauses 61 to 78, wherein the collagen composition, the collagen solution or the collagen matrix is ​​sterilized by a method selected from the group consisting of exposure to chloroform, virus filtration, sterile filtration, gamma irradiation, ultraviolet radiation, electron beam, and combinations thereof.

[0243] 80. The method of any one of clauses 61 to 79, wherein the collagen composition is sterilized by filtration.

[0244] 81. The method of any one of clauses 61 to 80, wherein the buffer solution further comprises about 0.3 mM to about 3 mM KH2PO4.

[0245] 82. The method of any one of clauses 61 to 81, wherein the buffer solution further comprises about 1 mM to about 10 M Na2HPO4.

[0246] 83. The method of any one of clauses 61 to 82, wherein the buffer solution further comprises about 0.1 mM to about 4 mM KCl.

[0247] 84. The method of any one of clauses 61 to 83, wherein the buffer solution further comprises about 0.02 M to about 0.3 M NaCl.

[0248] 85. The method of any one of clauses 61 to 84, wherein the buffer solution further comprises about 0.002N to about 0.02N NaOH.

[0249] 86. The method of any one of clauses 61 to 85, wherein the buffer solution further comprises about 0.5 wt % to about 5 wt % glucose.

[0250] 87. The method of any one of clauses 61 to 85, wherein the buffer solution comprises about 0.5 wt % or less glucose.

[0251] 88. The method of any one of clauses 61 to 87, further comprising adding cells to the collagen solution.

[0252] 89. The method of any one of clauses 61 to 88, wherein the matrix comprises collagen fibrils.

[0253] 90. A collagen matrix prepared according to the method of any one of clauses 61 to 89.

[0254] 91. The collagen matrix of clause 90, wherein the collagen matrix is ​​a medical implant.

[0255] 92. The collagen matrix of clause 91, wherein the medical graft has a use selected from the group consisting of: a tissue graft material, an injectable graft material, a wound dressing, a hemostatic dressing, a delivery vehicle for therapeutic cells, and a delivery vehicle for therapeutic agents.

[0256] 93. The collagen matrix of clause 90, wherein the collagen matrix is ​​used for research purposes.

[0257] 94. The collagen matrix of clause 93, wherein the collagen matrix is ​​used for drug toxicity testing or drug development.

[0258] 95. A kit comprising freeze-dried collagen, a hydrochloric acid solution and a buffer solution.

[0259] 96. The kit of clause 95, wherein the buffer solution comprises about 0.03 mM to about 0.2 mM MgCl2.

[0260] 97. The kit of clause 95, wherein the buffer solution comprises about 0.002 mM to about 0.02 mM MgCl2.

[0261] 98. The kit of clause 95, wherein the buffer solution comprises less than about 0.02 mM MgCl2.

[0262] 99. The kit of clause 95, wherein the buffer solution does not contain MgCl2.

[0263] 100. The kit of any one of clauses 95 to 99, wherein the buffer solution further comprises about 0.003 M to about 0.03 M KH2PO4.

[0264] 101. The kit of any one of clauses 95 to 100, wherein the buffer solution further comprises about 0.01 M to about 0.1 M Na2HPO4.

[0265] 102. The kit of any one of clauses 95 to 101, wherein the buffer solution further comprises about 0.001 M to about 0.04 M KCl.

[0266] 103. The kit of any one of clauses 95 to 102, wherein the buffer solution further comprises about 0.2 M to about 3.0 M NaCl.

[0267] 104. The kit of any one of clauses 95 to 103, wherein the buffer solution further comprises about 0.02N to about 0.2N NaOH.

[0268] 105. The kit of any one of clauses 95 to 104, wherein the buffer solution further comprises about 0.2 wt % to about 5 wt % glucose.

[0269] 106. The kit of any one of clauses 95 to 105, wherein the buffer solution comprises about 0.5 wt % or less glucose.

[0270] 107. The kit of any one of clauses 95 to 106, wherein the hydrochloric acid solution comprises about 0.005N hydrochloric acid to about 0.1N hydrochloric acid.

[0271] 108. The kit of any one of clauses 95 to 107, wherein the buffer solution is capable of polymerizing collagen using a single mixing step comprising mixing the buffer solution with the lyophilized collagen reconstituted in the hydrochloric acid solution.

[0272] 109. The kit of any one of clauses 95 to 108, wherein the lyophilized collagen, the hydrochloric acid solution and the buffer solution are in separate containers.

[0273] 110. The kit of any one of clauses 95 to 109, further comprising instructions for use of the components of the kit.

[0274] 111. A method of preparing a matrix, the method comprising polymerizing collagen using a single mixing step, the single mixing step comprising mixing a collagen composition with a buffer solution to form a collagen solution, wherein the collagen in the collagen solution is polymerized to form the matrix.

[0275] 112. The method of any one of clauses 1 to 33, 61 to 89 or 111, wherein the collagen is soluble collagen.

[0276] 113. The method of any one of clauses 1 to 19, 21 to 33, 61 to 79, 81 to 89 or 111 to 112, wherein the collagen composition, the collagen solution and / or the collagen matrix is ​​sterilized using ultraviolet radiation.

[0277] 114. The method of clause 113, wherein the collagen matrix resulting from the polymerization of collagen retains polymeric properties relative to a non-irradiated collagen composition, a non-irradiated collagen solution, or a non-irradiated collagen matrix, respectively.

[0278] 115. The method of clause 114, wherein the polymer property is shear storage modulus.

[0279] 116. The method of any one of clauses 113 to 115, wherein the radiation dose ranges from about 5 mJ / cm 2About 800mJ / cm 2 .

[0280] 117. The method of any one of clauses 113 to 115, wherein the radiation dose ranges from about 30 mJ / cm 2 About 300mJ / cm 2 .

[0281] 118. The method of any one of clauses 113 to 117, wherein the sterilization inactivates viruses.

[0282] 119. The collagen matrix of any one of clauses 34 to 38 or 90 to 94, wherein the collagen matrix is ​​sterilized using ultraviolet radiation.

[0283] 120. The collagen matrix of clause 119, wherein the collagen matrix retains polymeric properties relative to a non-irradiated collagen matrix.

[0284] 121. The collagen matrix of clause 120, wherein the polymeric property is shear storage modulus.

[0285] 122. The collagen matrix of any one of clauses 119 to 121, wherein the radiation dose ranges from about 5 mJ / cm 2 About 800mJ / cm 2 .

[0286] 123. The collagen matrix of any one of clauses 119 to 121, wherein the radiation dose ranges from about 30 mJ / cm 2 About 300mJ / cm 2 .

[0287] 124. The collagen matrix of any one of clauses 119 to 123, wherein the sterilization inactivates viruses.

[0288] 125. The kit of any one of clauses 39 to 60 or 95 to 110, wherein the collagen composition or freeze-dried collagen is sterilized using ultraviolet radiation.

[0289] 126. The kit of clause 125, wherein the collagen matrix resulting from the polymerization of collagen retains polymeric properties relative to a non-irradiated collagen composition or non-irradiated freeze-dried collagen, respectively.

[0290] 127. The kit of clause 126, wherein the polymeric property is shear storage modulus.

[0291] 128. A kit as described in any of clauses 125 to 127, wherein the radiation dose ranges from about 5 mJ / cm 2About 800mJ / cm 2 .

[0292] 129. A kit as described in any of clauses 125 to 127, wherein the radiation dose ranges from about 30 mJ / cm 2 About 300mJ / cm 2 .

[0293] 130. The kit of any one of clauses 125 to 129, wherein the sterilization inactivates viruses.

[0294] 131. The method of any one of clauses 1 to 19, 21 to 33, 61 to 79, 81 to 89 or 111 to 118, wherein the collagen composition, the collagen solution and / or the collagen matrix is ​​sterilized using UVC irradiation.

[0295] 132. The method of any one of clauses 1 to 19, 21 to 33, 61 to 79, 81 to 89 or 111 to 118, wherein the collagen composition, the collagen solution and / or the collagen matrix is ​​sterilized using UVC irradiation and sterile filtration.

[0296] 133. The collagen matrix of any one of clauses 34 to 38, 90 to 94 or 119 to 124, wherein the collagen matrix is ​​sterilized using UVC irradiation.

[0297] 134. The collagen matrix of any one of clauses 34 to 38, 90 to 94 or 119 to 124, wherein the collagen matrix is ​​sterilized using UVC irradiation and sterile filtration.

[0298] 135. The kit of any one of clauses 39 to 60, 95 to 110 or 125 to 130, wherein the collagen composition or the lyophilized collagen is sterilized using UVC irradiation.

[0299] 136. The kit of any one of clauses 39 to 60, 95 to 110 or 125 to 130, wherein the collagen composition or the lyophilized collagen is sterilized using UVC irradiation and sterile filtration.

[0300] As will be understood by those skilled in the art, polymerization, self-assembly, self-assembled, fibril formation and matrix forming ability have the same meaning, and as will be understood by those skilled in the art, the matrix can be in fibril form. To prepare collagen for use in the methods and compositions described herein, any method for preparing collagen known in the art can be used. In illustrative embodiments, collagen can be prepared by the methods described in the following documents: Bailey JL, Critser PJ, Whittington C, Kuske JL, Yoder MC, Voytik-Harbin SL; Collagen oligomers modulate physical and biological properties of three-dimensional self-assembled matrices, Biopolymers (2011) 95 (2): 77-93; Kreger ST, Bell BJ, Bailey J, Stites E, Kuske J, Waisner B, Voytik-Harbin SL; Polymerization and matrix physical properties as important design considerations for soluble collagen formulations[Polymerization and matrix physical properties as important design considerations for soluble collagen formulations], Biopolymers [Biopolymers] (2010) 93(8):690-707; U.S. Patent Application Publication No. 20080268052; or U.S. Patent Application Publication No. 20120027732, each of which is incorporated herein by reference.

[0301] In various illustrative embodiments, the collagen used in the methods and compositions described herein can be obtained from any suitable source of collagen known in the art. Exemplary collagen sources generally include submucosal tissue (U.S. Pat. Nos. 4,902,508, 5,281,422, and 5,275,826), pericardial tissue, bladder submucosal tissue, gastric submucosal tissue, liver basement membrane tissue, placental tissue, ovarian tissue, animal tail tissue, skin tissue (e.g., Gallop et al., Preparation and Properties of Soluble Collagens [soluble collagen preparation and properties], Meth. Enzymol. [enzymatic methods], 6: 635-641 (1963), incorporated herein by reference) and extracellular matrix tissue. In various embodiments, the type of collagen used in the methods and compositions described herein can be any suitable collagen type, including but not limited to type I collagen, type II collagen, type III collagen, or type IV collagen, or a combination thereof.

[0302] In one embodiment, tissue rich in collagen oligomers (e.g., porcine skin tissue) can also be used to obtain collagen for the methods and compositions described herein, or collagen can be obtained from cells that produce collagen oligomers (e.g., cells altered by recombinant technology to express collagen oligomers), or obtained by chemically cross-linking collagen to obtain collagen oligomers (e.g., using cross-linking agents known in the art). In various embodiments, the collagen used in the methods and compositions described herein may include oligomers or may consist of oligomers. In another embodiment, collagen may include oligomers and other forms of collagen, such as monomers, terminal collagens, and / or terminal collagens.

[0303] In another embodiment, the collagen can be soluble collagen or dissolved collagen. In embodiments where the collagen is soluble collagen or dissolved collagen, the collagen is substantially free of insoluble collagen but may contain some insoluble collagen. In another embodiment, the collagen consists of soluble collagen or dissolved collagen.

[0304] In various illustrative embodiments, collagen, collagen compositions, collagen matrices, collagen solutions, lyophilized collagen, and / or buffer solutions may be sterilized using sterilization techniques known in the art, including, but not limited to, propylene oxide or ethylene oxide treatment, gas plasma sterilization, gamma radiation (e.g., 1-4 megarads), ultraviolet radiation (e.g., UVC irradiation), electron beam, virus filtration, sterile filtration (e.g., using a 0.22 μm filter), chloroform exposure, and / or peracetic acid sterilization, and combinations thereof. In this embodiment, the sterilization process should not adversely affect the structure of the collagen being sterilized, the polymerization properties of the collagen, or the biological properties of the collagen. In various embodiments, the collagen may be sterilized before or after lyophilization (the lyophilization process is described below).

[0305] In ultraviolet radiation (e.g., UVC irradiation) embodiments, the collagen matrix produced by collagen polymerization can maintain polymerization properties relative to unirradiated collagen, unirradiated collagen compositions, unirradiated collagen matrices, unirradiated collagen solutions, or unirradiated freeze-dried collagen. In this embodiment, the polymerization properties can be selected from shear storage modulus, elastic modulus (Young's modulus), tensile modulus, compression modulus, fibril structure, proteolytic degradation, cell signaling, and combinations thereof. In various embodiments, the ultraviolet radiation dose (e.g., UVC irradiation) can range from about 5 mJ / cm 2 About 800mJ / cm 2 , about 5mJ / cm 2 About 700mJ / cm 2 , about 5mJ / cm 2 About 600mJ / cm 2 , about 5mJ / cm 2 About 500mJ / cm 2 , about 5mJ / cm 2 About 400mJ / cm 2 , about 5mJ / cm 2 About 300mJ / cm 2 , 5mJ / cm 2 About 200mJ / cm 2 , 5mJ / cm 2 About 100mJ / cm 2 , 5mJ / cm 2 to about 50mJ / cm 2 , about 30mJ / cm 2 About 800mJ / cm 2 , about 30mJ / cm 2 About 700mJ / cm 2 , about 30mJ / cm 2 About 600mJ / cm 2 , about 30mJ / cm 2 About 500mJ / cm 2 , about 30mJ / cm 2 About 400mJ / cm 2 , about 30mJ / cm 2 About 300mJ / cm 2 , about 30mJ / cm 2 About 200mJ / cm 2 , about 30mJ / cm 2 About 100mJ / cm 2 , about 30mJ / cm 2 to about 50mJ / cm2 , about 200mJ / cm 2 About 800mJ / cm 2 , about 300mJ / cm 2 About 800mJ / cm 2 , about 400mJ / cm 2 About 800mJ / cm 2 , about 500mJ / cm 2 About 800mJ / cm 2 , about 600mJ / cm 2 About 800mJ / cm 2 , about 50mJ / cm 2 About 300mJ / cm 2 , about 100mJ / cm 2 About 300mJ / cm 2 , or about 200mJ / cm 2 About 300mJ / cm 2 In all ultraviolet radiation embodiments described herein (e.g., UVC irradiation), sterilization inactivates viruses. In this embodiment, "inactivating viruses" means inactivating all viruses (whether infectious or not), reducing the number of infectious viruses, or inhibiting the activity of viruses (whether infectious or not).

[0306] In one aspect, the collagen used for the methods and compositions described herein can be purified by methods known in the art for purifying collagen. As used herein, "purification" refers to removing pollutants, including but not limited to cell pollutants, nucleotide pollutants and endotoxins. In various embodiments, the purity of collagen can be at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 99.5% to purify collagen by removing pollutants. In another embodiment, collagen can be separated. As used herein, "separation" refers to being substantially free of pollutants, including but not limited to cell pollutants, nucleotide pollutants and endotoxins.

[0307] In an illustrative embodiment, the collagen used in the methods and compositions described herein can be lyophilized and then reconstituted to form a collagen composition for mixing with a buffer solution as described herein. In this embodiment, the reconstruction of the lyophilized collagen is not a mixing step for collagen polymerization. As used herein, the term "lyophilized" refers to removing water from a protein, compound, or composition by, for example, freeze drying under vacuum. Any lyophilization method known to the technician can be used. In one aspect, the collagen can be lyophilized in an acid such as acetic acid, hydrochloric acid, formic acid, lactic acid, citric acid, sulfuric acid, or phosphoric acid. In another embodiment, the collagen can be lyophilized in water. In other illustrative embodiments, a cryoprotectant or a lyoprotectant or a combination thereof can be used during the lyophilization process.

[0308] In an illustrative aspect, lyophilized collagen can be reconstructed to form a collagen composition as described herein, for mixing with a buffer solution to polymerize collagen. In various illustrative embodiments, collagen can be reconstructed in an acidic solution or water. In various embodiments, the acidic solution may include acetic acid, hydrochloric acid, formic acid, lactic acid, citric acid, sulfuric acid or phosphoric acid. In illustrative embodiments, the acidic solution for reconstruction may have an acid concentration of about 0.005N to about 0.1N, about 0.005N to about 0.08N, about 0.005N to about 0.06N, about 0.005N to about 0.04N, about 0.005N to about 0.02N, about 0.005N to about 0.01N or about 0.01N. In one embodiment, the acid may be hydrochloric acid, and the hydrochloric acid may be the hydrochloric acid of about 0.005N to about 0.1N. In another embodiment, the acid may be hydrochloric acid, and the hydrochloric acid may be the hydrochloric acid of about 0.01N.

[0309] In an illustrative aspect, the concentration of collagen in the collagen composition or collagen solution can be about 0.1 mg / ml to about 40 mg / ml, about 0.1 mg / ml to about 5 mg / ml, or about 0.5 mg / ml to about 4 mg / ml. In other embodiments, the collagen concentration in the collagen composition or collagen solution can be about 0.05 to about 5.0 mg / ml, about 1.0 mg / ml to about 3.0 mg / ml, about 0.05 mg / ml to about 10 mg / ml, about 0.05 to about 20 mg / ml, about 0.05 to about 30 mg / ml, about 0.05 to about 40 mg / ml, about 0.05 to about 50 mg / ml, about 0.05 to about 60 mg / ml, about 0.05 to about 80 mg / ml, about 5 mg / ml to 10 mg / ml, about 5 mg / ml to 20 mg / ml, about 5 mg / ml to about 40 mg / ml, about 5 mg / ml to 60 mg / ml, about 5 mg / ml to about 100 mg / ml, about 20 mg / ml to about 40 mg / ml, about 20 mg / ml to 60 mg / ml, or about 20 mg / ml to about 100 mg / ml.

[0310] In an illustrative embodiment, the collagen composition is mixed with a buffer solution in a single step to polymerize collagen. In another embodiment, the collagen composition is mixed with a buffer solution in the absence of magnesium ions or manganese ions to polymerize collagen. In one embodiment, the collagen composition is mixed with a buffer solution to form a collagen solution, and the collagen solution is incubated at a temperature greater than about 25°C to promote the polymerization of collagen in the collagen solution. In another embodiment, the collagen solution can be incubated at about 37°C to promote the polymerization of collagen in the collagen solution. In various other embodiments, the collagen solution can be incubated at about 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 38°C, 39°C or 40°C to promote the polymerization of collagen in the collagen solution. In another embodiment, the collagen solution can be incubated at about 25°C to about 40°C to promote the polymerization of collagen in the collagen solution. In other embodiments, polymerization can be performed at a temperature above 20° C., or at a temperature selected from the range of about 20° C. to about 40° C. In these embodiments, collagen can be polymerized to form fibrils similar to those found in vivo.

[0311] In one embodiment, the buffer solution to be mixed with the collagen composition to form the collagen solution may include about 0.03 mM to about 0.2 mM MgCl2, about 0.002 mM to about 0.02 mM MgCl2, less than about 0.02 mM MgCl2, or no MgCl2. In other embodiments, the buffer solution to be mixed with the collagen composition to form the collagen solution may include about 0.3 mM to about 3 mM KH2PO4, about 1 mM to about 10 M Na2HPO4, about 0.1 mM to about 4 mM KCl, about 0.02 M to about 0.3 M NaCl, and about 0.002 N to about 0.02 N NaOH. In another embodiment, the buffer solution to be mixed with the collagen composition to form the collagen solution may include about 0.5 wt % to about 5 wt % glucose, about 0.5 wt % glucose or less glucose, or no glucose.

[0312] In one aspect, the buffer solution can be diluted from 10X, 5X, 2X, or any suitable starting concentration to prepare a 1X buffer solution having any of the component concentrations in the previous paragraph. In one aspect, the kits described herein can include a buffer solution having a concentration of 10X, 5X, or 2X, or any suitable starting concentration, for dilution to prepare a 1X buffer solution. According to one embodiment, a 10X buffer solution can include the following components at the following concentrations:

[0313] 1.37M NaCl

[0314] 0.027M KCl

[0315] 0.081M Na2HPO4

[0316] 0.015M KH2PO4

[0317] 0.1N NaOH

[0318] and optionally 55.5 mM glucose

[0319] In another embodiment, a 1X buffer solution may include the following components at the following concentrations:

[0320] 0.137M NaCl

[0321] 0.0027M KCl

[0322] 0.0081M Na2HPO4

[0323] 0.0015M KH2PO4

[0324] 0.01N NaOH

[0325] and optionally 5.55 mM glucose

[0326] In these embodiments, NaOH is present in the buffer solution. In previously known conventional methods for polymerizing collagen, NaOH is added separately as an additional mixing step in the collagen polymerization process. In another illustrative embodiment, calcium chloride may be present in the buffer solution at a concentration of about 0.4 mM to about 2.0 mM.

[0327] In various embodiments, the buffer in the buffer solution can be selected from the group consisting of phosphate buffered saline (PBS), tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), 3-(N-morpholino)propanesulfonic acid (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), N-(2-acetylamino)-2-aminoethanesulfonic acid (ACES), N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES) and 1,3-bis((trishydroxymethyl)methylamino)propane (Bis-Tris propane). In one embodiment, the buffer is PBS.

[0328] In various illustrative embodiments, the pH of the collagen solution used for collagen polymerization is selected from the range of about 5.0 to about 11, about 6.0 to about 9.0, about 6.5 to about 8.5, and in another embodiment, the pH is about 7.3 to about 7.4.

[0329] In various embodiments, nutrients can be added to the collagen solution before or after the completion of collagen polymerization or during the collagen polymerization process, including minerals, amino acids, sugars, peptides, proteins, vitamins, or glycoproteins (such as laminin and fibronectin) that promote cell proliferation, hyaluronic acid, or growth factors (such as epidermal growth factor, platelet-derived growth factor, transforming growth factor β or fibroblast growth factor) and glucocorticoids (such as dexamethasone). According to another embodiment, cells can be added to the collagen solution before or after the completion of collagen polymerization or during the collagen polymerization process. In various embodiments, cells can be selected from the group consisting of epithelial cells, endothelial cells, mesoderm-derived cells, mesothelial cells, synoviocytes, neurons, glial cells, osteoblasts, fibroblasts, chondrocytes, tendon cells, smooth muscle cells, skeletal muscle cells, cardiomyocytes, multipotent progenitor cells (e.g., stem cells, including bone marrow progenitor cells), adipocytes and osteoblasts.

[0330] In one embodiment, a collagen matrix prepared according to any one of the methods described herein is provided. In one aspect, the collagen matrix can be a medical implant. In one embodiment, the medical implant has the purpose of being selected from the group consisting of: a tissue graft material, an injectable graft material, a wound dressing, a hemostatic dressing, a delivery carrier for therapeutic cells, and a delivery carrier for a therapeutic agent. In another embodiment, the method described herein can be used to prepare a bio-ink formulation for printing tissues or organs. In another embodiment, the collagen matrix is ​​used for research purposes, such as drug toxicity testing or drug development. In one embodiment, the matrix prepared by the method described herein can be used as a substrate for endogenous tissue regeneration (e.g., remodeling) at the implantation site, and these matrixes can have the characteristics of the damaged or diseased tissues replaced by them at the implantation or injection site.

[0331] In an illustrative embodiment, the matrices described herein may contain fibrils having a fibril area fraction (defined as the area percentage of the total area occupied by the fibrils in a cross-section of the matrix) or a fibril volume fraction (the area percentage of the total area occupied by the fibrils in three dimensions) of about 0.1% to about 100%, about 0.5% to about 100%, about 0.5% to about 26%, about 1% to about 100%, about 1% to about 26%, about 1% to about 7%, about 1% to about 15%, about 7% to about 26%, about 20% to about 30%, about 20% to about 50%, about 20% to about 70%, about 20% to about 100%, about 30% to about 50%, about 30% to about 70%, or about 30% to about 100%, and / or a modulus (e.g., elastic or linear modulus (defined by the slope of the linear region of a stress-strain curve obtained using conventional mechanical testing protocols; i.e., stiffness), compression modulus, or shear storage modulus) of about 0.5 kPa to about 40 kPa, about 30 kPa to 100 kPa, about 30 kPa to about 1000 kPa, about 30 kPa to about 10000 kPa, about 30 kPa to about 70000 kPa, about 100 kPa to 1000 kPa, about 100 kPa to about 10000 kPa, or about 100 kPa to about 70000 kPa.

[0332] In another embodiment, a test kit comprising lyophilized collagen, hydrochloric acid solution and buffer solution is described. In yet another embodiment, a test kit comprising a collagen composition and a buffer solution is provided. In these test kit embodiments, the buffer solution may include about 0.03mM to about 0.2mM MgCl2, about 0.002mM to about 0.02mM MgCl2, less than about 0.02mM MgCl2, or the buffer solution does not contain MgCl2. In various embodiments, the buffer solution further includes about 0.003M to about 0.03M KH2PO4, about 0.01M to about 0.1M Na2HPO4, about 0.001M to about 0.04M KCl, about 0.2M to about 3.0M NaCl and about 0.02N to about 0.2N NaOH. In another aspect, the buffer solution may include about 0.2% by weight to about 5% by weight of glucose, about 0.5% by weight of glucose or less glucose or does not contain glucose.

[0333] In one aspect, in a kit embodiment with a hydrochloric acid solution, the hydrochloric acid solution may include hydrochloric acid from about 0.005N to about 0.1N. In one aspect, in a kit embodiment with lyophilized collagen, a hydrochloric acid solution, and a buffer solution, the lyophilized collagen, the hydrochloric acid solution, and the buffer solution are in separate containers. In one aspect of an embodiment with a collagen composition and a buffer solution, the concentration of collagen in the collagen composition may be from about 0.1mg / ml to about 40mg / ml or from about 0.1mg / ml to about 5mg / ml. In this embodiment, the collagen composition and the buffer solution may be in separate containers (such as sterilized vials or separate compartments of a double-barreled syringe including a mixing element). In any one of the kit embodiments described herein, the kit may include instructions for use of the kit components. In any one of the kit embodiments described herein, the buffer solution is capable of polymerizing collagen using a single mixing step, which includes mixing the buffer solution with the lyophilized collagen reconstituted in the hydrochloric acid solution or with the collagen composition.

[0334] In another embodiment, the kit is provided with collagen in lyophilized form and further comprises a buffer solution as described herein and a solution of an acid (such as acetic acid or another dilute acid including, for example, hydrochloric acid, formic acid, lactic acid, citric acid, sulfuric acid, or phosphoric acid) for reconstituting the lyophilized collagen.

[0335] The following examples further illustrate specific embodiments. These examples are provided for illustrative purposes only and should not be construed as limiting the present invention in any way.

[0336] Example 1

[0337] Preparation of collagen composition

[0338] Type I collagen oligomers were derived from dermis of captive porcine and prepared as described previously (Bailey JL, Critser PJ, Whittington C, Kuske JL, Yoder MC, Voytik-Harbin SL, Collagen oligomers modulate physical and biological properties of three-dimensional self-assembled matrices, Biopolymers (2011) 95(2):77–93, and Kreger ST, Bell BJ, Bailey J, Stites E, Kuske J, Waisner B, Voytik-Harbin SL, Polymerization and matrixphysical properties as important design considerations for soluble Collagen formulations [Polymerization and matrix physical properties as important design considerations for soluble collagen formulations], Biopolymers [Biopolymers] (2010) 93 (8): 690-707, both of which are incorporated herein by reference). Lyophilized collagen oligomers were dissolved in 0.01 N hydrochloric acid before use. Research grade oligomers were sterilized by exposure to chloroform at 4°C. Medical grade oligomers were sterile filtered using a 0.22 μm Millex-GP PES Express syringe filter (Millipore, SLGPO33RS). Collagen concentration was determined using the Sirius Red (Direct Red 80) assay. Oligomer preparations were standardized based on purity and polymerization ability according to ASTM International consensus standard F3089-14 (ASTM Standard F3089, 2014, "Standard Guide for Characterization and Standardization of Polymerizable Collagen-Based Products and Associated Collagen-Cell Interactions", ASTM International, West Conshohocken, PA, F3089-14).The polymerization capacity is defined by the matrix shear storage modulus (G') which varies with the collagen concentration of the polymerization reaction. Multi-step self-assembly was performed and involved 3 reagents, namely 10X Polymerization Buffer PLUS, 0.1N NaOH and polymerization supplement. Single-step self-assembly was performed in the absence of MgCl2 using 10X self-assembly reagent prepared according to the following recipe (diluted 1:10):.

[0339] 2g KH2PO4 (FW 136.09)

[0340] 11.5g Na2HPO4 (FW 141.96)

[0341] 2g KCl (FW 74.55)

[0342] 10g glucose

[0343] 80g NaCl (FW 58.44)

[0344] 20ml 5N NaOH

[0345] All reagents were added to Milli-Q filtered water to a final volume of 1 liter and sterile filtered (0.22 μm).Integra Flowable was obtained from Integra Life Sciences, Plainsboro, NJ and processed according to the manufacturer's instructions.

[0346] Example 2

[0347] Viscoelasticity testing

[0348] As previously described (Kreger et al., 2010), the viscoelastic properties of the self-assembled collagen matrix were determined using an oscillatory shear mode on an AR2000 rheometer (TA Instruments, New Castle, DE). The samples were polymerized on the rheometer stage for 30 minutes and then subjected to a shear strain sweep from 0.1% to 4% strain at 1 Hz. The shear storage modulus (G') at 1% strain was used as a measure of matrix stiffness.

[0349] Example 3

[0350] Cell culture and preparation of three-dimensional collagen-fibrillar tissue constructs

[0351] Low-passage human adipose-derived stem cells (hASCs) were obtained from Zen-Bio, Research Triangle Park, NC, and cultured in growth medium consisting of Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Carlsbad, CA), 10% fetal bovine serum (FBS), 100 U / mL penicillin, and 100 U / mL streptomyosin (Invitrogen, Grand Island, NY). hASCs were grown and maintained at 37°C in a humidified atmosphere containing 5% carbon dioxide in air. Cells were maintained below 80% confluence and used in experiments at passages 6 to 9.

[0352] Cell-encapsulated collagen-fibril tissue constructs were prepared by suspending hASC (300,000 cells / ml) in a neutralized oligomer (200Pa) solution. Neutralization was achieved using a multi-step or single-step process and reagent. After 3 days of culture, the tissue constructs were fixed in 3% paraformaldehyde and stained with phalloidin to visualize the actin cytoskeleton. For 3D qualitative analysis, the tissue constructs were imaged using an Olympus FluoView FV-1000 confocal system suitable for an inverted microscope (IX81, Olympus Corporation, Tokyo, Japan).

[0353] Example 4

[0354] Subcutaneous injection in mice

[0355] C57BL / 6 mice (n=5) obtained from Harlan Laboratories, Indianapolis, Indiana were initially anesthetized in a 1 L induction chamber and then maintained unconscious using a coaxial nose cone non-rebreathing system administering 1%-3% isoflurane in 1.5 L / min of medical grade air. Sterile eye lubricant was applied and the animals were placed on an adjustable heating table set at 44°C to maintain internal body temperature close to 37°C. Heart rate, respiratory rate, and body temperature were monitored every 15 minutes using table electrodes and a rectal probe, respectively. Dorsal hair was removed using scissors and depilatory cream (Nair, Church & Dwight Co., Inc. Ewing, NJ). Experimental groups included 1) research grade oligomer (500Pa), 2) medical grade oligomer (500Pa), 3) Integra Flowable, 4) phosphate buffered saline (PBS), or 5) no treatment control. The oligomer, Integra Flowable, and PBS formulations were injected subcutaneously (200 μl) on both sides of the back parallel to the sagittal plane. The oligomer and PBS formulations were injected using 27G, 1 / 2-inch needle, while Integra Flowable requires 18G, 1 / 2-inch needles were used because of material consistency and clogging with smaller needle sizes. Four weeks later, animals were euthanized and the implantation site along with a wide margin of surrounding host tissue was harvested. All specimens were formalin-fixed, paraffin-embedded, thinly sectioned, and stained with hematoxylin-eosin (H&E) and Masson's trichrome.

[0356] Example 5

[0357] Development and validation of single-step self-assembly processes and reagents

[0358] The single-step self-assembly process and reagents included maintaining i) physiologically relevant conditions and reagents and ii) the polymerization capacity observed with the established multi-step process. Initial attempts to combine all reagents used in the multi-step process, including 10X Polymerization Buffer PLUS, Polymerization Supplement, and NaOH, produced an unstable solution that formed a flocculent precipitate. However, when MgCl2 was removed, no precipitation was observed even with prolonged storage at 4°C. Based on these results, subsequent studies were performed to evaluate the polymerization capacity and in vitro cellular response. Compared to the multi-step process, the single-step process produced similar polymerization capacity curves and similar in vitro cellular behavior and morphology, respectively. Figure 1 and Figure 2Preliminary studies were also performed to show the utility of the single-step self-assembly for 3D bioprinting applications. More specifically, tissue constructs containing a continuous gradient of collagen-fibril density were printed using a custom-designed single-nozzle bioprinting device using oligomers, 10X self-assembly reagents, and diluents. The new single-step collagen self-assembly process and associated formulations are shown in Figure 3 and Figure 4 shown.

[0359] Example 6

[0360] Development and validation of sterilization of collagen polymers

[0361] Additional studies were conducted to evaluate sterilization methods that would support scale-up manufacturing and regulatory approval of a medical-grade oligomer product. Sterile filtration was performed using a conventional 0.22 μm syringe-based filter device. Because the oligomer represents a soluble molecular solution, it is amenable to sterile filtration. The oligomer formulation (500 Pa) showed statistically similar (p>0.05) polymerization kinetics and capacity before (458±55 Pa) and after (434±49) sterile filtration. Additional studies confirmed that similar in vivo tissue responses were obtained with research-grade and medical-grade oligomer formulations. Furthermore, the in vivo tissue responses obtained using single-step polymerization of research-grade oligomers were consistent with those obtained using a multi-step polymerization process (see Figure 5 ).

[0362] Example 7

[0363] Effects of UV-irradiation on collagen matrix properties

[0364] Monochromatic ultraviolet radiation at 254 nm (UVC) was generated by a flat collimated beam system using a low-pressure mercury lamp source. A thin layer (1 mm) of collagen solution was placed in a culture dish and irradiated with 0 (untreated control), 30 mJ / cm 2 (1 minute irradiation) and 300mJ / cm 2 The polymerizability and related viscoelasticity of the treated samples were measured as described in Example 2 and compared with untreated controls. For exposure to 0, 30 and 300 mJ / cm 2 The shear storage modulus measurements for the oligomer solutions irradiated with UVC at doses of 2.5 and 1.5 were statistically similar ( Figure 7 ).

Claims

1. A method for preparing a collagen matrix, the method comprising polymerizing oligomeric collagen using a single mixing step, the mixing step consisting of mixing a soluble oligomeric collagen solution with a buffer solution to form a mixed collagen solution, wherein the buffer solution consists of 0.003M to 0.03M KH2PO4, 0.01M to 0.1M Na2HPO4, 0.001M to 0.04M KCl, 0.2M to 3.0M NaCl and 0.02N to 0.2N NaOH, and wherein the polymerization of the soluble oligomeric collagen in the mixed collagen solution results in the formation of the collagen matrix.

2. The method according to claim 1, wherein: The soluble oligomeric collagen solution, the mixed collagen solution or the collagen matrix is ​​sterilized by a method selected from the group consisting of exposure to chloroform, virus filtration, sterile filtration, ultraviolet radiation, gamma irradiation, electron beam and combinations thereof.

3. A collagen matrix prepared according to the method according to any one of claims 1 to 2.

4. A kit comprising a soluble oligocollagen solution and a buffer solution, wherein: The buffer solution is capable of polymerizing the soluble oligomeric collagen to form a matrix using a single mixing step between the two solutions, the mixing step comprising mixing the soluble oligomeric collagen solution with the buffer solution, wherein the buffer solution consists of 0.003M to 0.03M KH2PO4, 0.01M to 0.1M Na2HPO4, 0.001M to 0.04M KCl, 0.2M to 3.0M NaCl and 0.02N to 0.2N NaOH.

5. A method for preparing a collagen matrix, the method comprising polymerizing soluble oligomeric collagen by: A soluble oligomeric collagen solution is mixed with a buffer solution to form a mixed collagen solution, wherein the buffer solution consists of 0.003M to 0.03M KH2PO4, 0.01M to 0.1M Na2HPO4, 0.001M to 0.04M KCl, 0.2M to 3.0M NaCl and 0.02N to 0.2N NaOH, and wherein polymerization of the oligomeric collagen in the collagen solution results in the formation of the collagen matrix.

6. The method according to claim 5, wherein: The soluble oligomeric collagen solution, the mixed collagen solution or the collagen matrix is ​​sterilized by a method selected from the group consisting of exposure to chloroform, virus filtration, sterile filtration, ultraviolet radiation, gamma irradiation, electron beam and combinations thereof.

7. A collagen matrix prepared according to the method of claim 5 or 6.

8. The method according to any one of claims 1-2 or any one of claims 5-6, wherein: The soluble oligomeric collagen solution, the mixed collagen solution and / or the collagen matrix are sterilized using ultraviolet radiation.

9. The method according to claim 8, wherein: The collagen matrix produced by polymerization of soluble oligomeric collagen retains polymeric properties relative to a non-irradiated soluble oligomeric collagen solution, a non-irradiated mixed collagen solution, or a non-irradiated collagen matrix, respectively.

10. The method according to claim 9, wherein: The polymer property is the shear storage modulus or in vivo tissue response.

11. The method according to claim 8, wherein: Radiation dose ranges from 30mJ / cm 2 Up to 300mJ / cm 2 .

12. The method according to claim 8, wherein: This sterilization inactivates the virus.

13. The collagen matrix according to claim 3 or 7, wherein: The collagen matrix was sterilized using ultraviolet radiation.

14. The collagen matrix according to claim 13, wherein The collagen matrix retains polymeric properties relative to non-irradiated collagen matrix.

15. The collagen matrix according to claim 14, wherein The polymer property is the shear storage modulus or in vivo tissue response.

16. The collagen matrix according to claim 13, wherein Radiation dose ranges from 30mJ / cm 2 Up to 300mJ / cm 2 .

17. The collagen matrix according to claim 13, wherein This sterilization inactivates the virus.

18. The kit according to claim 4, wherein The soluble oligomeric collagen solution is sterilized using ultraviolet radiation.

19. The kit according to claim 18, wherein The collagen matrix produced by collagen polymerization retains polymeric properties relative to non-irradiated soluble oligomeric collagen solutions.

20. The kit according to claim 19, wherein The polymer property is the shear storage modulus or in vivo tissue response.

21. The kit according to claim 18, wherein Radiation dose ranges from 30mJ / cm 2 Up to 300mJ / cm 2 .

22. The kit according to claim 18, wherein This sterilization inactivates the virus.

23. The method according to any one of claims 1-2, or any one of claims 5-6, or any one of claims 9-12, wherein: The soluble oligomeric collagen solution, the mixed collagen solution and / or the collagen matrix are sterilized using UVC irradiation.

24. The method according to claim 23, wherein: The soluble oligomeric collagen solution, the mixed collagen solution and / or the collagen matrix are sterilized using UVC irradiation and sterile filtration.

25. The collagen matrix according to claim 13, wherein The collagen matrix was sterilized using UVC irradiation.

26. The collagen matrix according to claim 25, wherein The collagen matrix was sterilized using UVC irradiation and sterile filtration.

27. The kit according to claim 18, wherein The soluble oligomeric collagen solution was sterilized using UVC irradiation.

28. The kit according to claim 27, wherein The soluble oligomeric collagen solution was sterilized using UVC irradiation and sterile filtration.